ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
2,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2,4,Respiratory syncytial virus infection,Respiratory syncytial viral infections,Viral infectious disorders,Infec,N
3,1,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
4,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4,2,Bacterial infection,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
4,3,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
4,4,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
4,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
4,6,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
4,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4,8,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
5,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
5,2,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
5,3,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
5,4,Drug dose titration not performed,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
5,5,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
5,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
5,7,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
5,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
5,9,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
6,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
6,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
6,3,Clostridium difficile infection,Clostridia infections,Bacterial infectious disorders,Infec,N
6,4,Immunosuppression,Immunodeficiency disorders NEC,Immunodeficiency syndromes,Immun,N
6,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
6,6,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
6,7,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
6,8,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
6,9,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
7,1,Blood uric acid increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
7,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
8,1,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
9,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
9,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
9,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
10,1,Peroneal nerve palsy,Mononeuropathies,Peripheral neuropathies,Nerv,N
11,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
12,1,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
13,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
13,2,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,Y
13,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,4,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
13,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
13,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
13,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
14,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
14,2,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
15,1,Fluid imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
15,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
15,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
15,4,Tachyarrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
16,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
16,2,Neurological decompensation,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
16,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
17,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
17,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
18,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
19,1,Biopsy bone marrow,Bone marrow and immune tissue histopathology procedures,Haematology investigations (incl blood groups),Inv,N
19,2,Bone marrow transplant,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
19,3,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
20,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
20,2,Blood lactic acid increased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
20,3,Blood pH decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
20,4,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
20,5,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
20,6,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
20,7,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
20,8,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
20,9,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
21,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,Y
22,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
22,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
22,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
23,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
23,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
23,3,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
24,1,Blepharospasm,Eyelid movement disorders,Ocular neuromuscular disorders,Eye,N
24,2,Gastrointestinal toxicity,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
25,1,Chronic lymphocytic leukaemia refractory,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
25,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
25,4,Hypokinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
25,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
26,1,Chronic lymphocytic leukaemia transformation,Leukaemias chronic lymphocytic,Leukaemias,Neopl,Y
27,1,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
27,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
27,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
27,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
28,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
28,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
29,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
29,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
30,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
30,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
31,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
31,2,Lung consolidation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
31,3,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
31,4,Mantle cell lymphoma refractory,Mantle cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
31,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
31,6,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
31,7,Pulmonary vascular disorder,Vascular pulmonary disorders NEC,Pulmonary vascular disorders,Resp,N
31,8,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
32,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
32,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
33,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
34,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
35,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
35,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
36,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,Y
37,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,Y
38,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
38,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
38,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
38,4,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
38,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
39,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
40,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
40,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
41,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
42,1,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
42,2,Lymphocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
42,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
43,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
43,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
44,1,Alanine aminotransferase abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
44,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
44,3,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
44,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
45,1,Epstein-Barr virus infection,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
45,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
46,1,Transplant,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
47,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
47,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
47,3,Neck mass,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
47,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
47,5,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
48,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
48,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
48,3,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
49,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
50,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
51,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
51,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
52,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
53,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
54,1,Allogenic stem cell transplantation,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
54,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
54,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
54,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
55,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
55,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
56,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
56,2,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
57,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
57,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
58,1,Acute leukaemia,Leukaemias acute NEC,Leukaemias,Neopl,Y
58,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
59,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
59,2,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
60,1,Campylobacter gastroenteritis,Campylobacter infections,Bacterial infectious disorders,Infec,N
60,2,Food poisoning,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
61,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
62,1,Granulocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
62,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
62,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
63,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
63,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
63,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
63,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
63,5,Transplant,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
64,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
64,2,Transplant,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
65,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
65,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
65,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
66,1,Chronic lymphocytic leukaemia transformation,Leukaemias chronic lymphocytic,Leukaemias,Neopl,Y
66,2,Lymphoma,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,N
67,1,Non-Hodgkin's lymphoma,Non-Hodgkin's lymphomas NEC,Lymphomas non-Hodgkin's unspecified histology,Neopl,N
67,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
67,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
67,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
68,1,Abdominal lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
68,2,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
68,3,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
68,4,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
69,1,Complications of transplant surgery,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,N
69,2,Post procedural infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
69,3,Transplant,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
70,1,Allogenic stem cell transplantation,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
71,1,B-cell lymphoma,B-cell lymphomas NEC,Lymphomas non-Hodgkin's B-cell,Neopl,N
71,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
72,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
72,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
73,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
73,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
73,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
74,1,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
74,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
75,1,Idiopathic neutropenia,Neutropenias,White blood cell disorders,Blood,N
76,1,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
76,2,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
77,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
78,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
78,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
78,3,Haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,N
79,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
80,1,B-cell prolymphocytic leukaemia,B-cell small lymphocytic lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
80,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
80,3,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
80,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
81,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
82,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
83,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
83,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
84,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
84,2,Minimal residual disease,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
85,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
85,2,Blood calcium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
85,3,Blood magnesium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
85,4,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
85,5,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
85,6,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
85,7,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
85,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
85,9,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
86,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
87,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
88,1,Bone marrow transplant,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
88,2,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
88,3,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
89,1,Bone marrow transplant,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
89,2,Complications of bone marrow transplant,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,Y
89,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
90,1,Bone marrow transplant,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
90,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
91,1,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
92,1,Chronic lymphocytic leukaemia recurrent,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
93,1,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
93,2,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
93,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
93,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
94,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
94,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
95,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
95,2,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
95,3,Arterial haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
95,4,Flank pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
95,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
95,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
95,7,Renal aneurysm,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
95,8,Renal infarct,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
95,9,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
95,10,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
95,11,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
95,12,Subcapsular renal haematoma,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
95,13,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
95,14,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
96,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
96,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
97,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
98,1,Arterial haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
98,2,Chromosomal deletion,Chromosomal abnormalities NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
98,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
98,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
98,5,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
98,6,Renal haemorrhage,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
98,7,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
98,8,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
99,1,Pericarditis,Noninfectious pericarditis,Pericardial disorders,Card,N
100,1,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
101,1,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
102,1,B-cell small lymphocytic lymphoma,B-cell small lymphocytic lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
103,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
103,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
103,3,Sinus disorder,Paranasal sinus disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
103,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
104,1,Bedridden,Disability issues,Lifestyle issues,SocCi,N
104,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
104,3,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
105,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
106,1,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
107,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
107,2,Lower limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
108,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
108,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
109,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
110,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
110,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
111,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
111,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
112,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
113,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
113,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
114,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
114,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
115,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
115,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
115,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
116,1,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
117,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
117,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
118,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
118,2,Stem cell transplant,Haematological therapeutic procedures NEC,Haematological and lymphoid tissue therapeutic procedures,Surg,N
119,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
120,1,Follicular lymphoma,Follicular lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
121,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
121,2,Neck mass,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
121,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
121,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
122,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
122,2,Streptococcal infection,Streptococcal infections,Bacterial infectious disorders,Infec,N
123,1,Deafness,Hearing losses,Hearing disorders,Ear,N
123,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
124,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
124,2,Streptococcal infection,Streptococcal infections,Bacterial infectious disorders,Infec,N
125,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
126,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
126,2,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
127,1,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
127,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
128,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
128,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
129,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
130,1,Lymphoma,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,Y
131,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
131,2,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
131,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
131,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
131,5,Hodgkin's disease,Hodgkin's disease NEC,Lymphomas Hodgkin's disease,Neopl,N
132,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
133,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
133,2,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
134,1,Multimorbidity,General signs and symptoms NEC,General system disorders NEC,Genrl,N
134,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
134,3,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
135,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
136,1,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
137,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
137,2,Transplant,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
138,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
139,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
140,1,Acute myeloid leukaemia refractory,Leukaemias acute myeloid,Leukaemias,Neopl,Y
140,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
140,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
140,4,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
140,5,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
141,1,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
142,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
142,2,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
142,3,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
142,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
142,5,Oliguria,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
142,6,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
142,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
142,8,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
142,9,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
142,10,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
142,11,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
143,1,Gastrointestinal carcinoma,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
144,1,Autoimmune disorder,Autoimmune disorders NEC,Autoimmune disorders,Immun,N
144,2,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
144,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
145,1,Chronic lymphocytic leukaemia recurrent,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
145,2,Chronic lymphocytic leukaemia refractory,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
145,3,Impaired quality of life,Social issues NEC,Lifestyle issues,SocCi,N
145,4,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
145,5,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
146,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
146,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
146,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
147,1,Autoimmune haemolytic anaemia,Anaemias haemolytic immune,Haemolyses and related conditions,Blood,N
147,2,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
148,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
149,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
150,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,Y
151,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
151,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
151,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
152,1,Abdominal mass,Abdominal findings abnormal,Gastrointestinal signs and symptoms,Gastr,N
153,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
154,1,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
155,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
155,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
155,3,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
156,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
157,1,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
158,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
159,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
159,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
159,3,Erythropoiesis abnormal,Red blood cell abnormal findings NEC,Red blood cell disorders,Blood,N
159,4,Granulocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
159,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
159,6,Megakaryocytes increased,Bone marrow and immune tissue histopathology procedures,Haematology investigations (incl blood groups),Inv,N
159,7,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
159,8,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
160,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,Y
161,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
162,1,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,Y
163,1,Blood disorder,Haematological disorders,Haematological disorders NEC,Blood,N
163,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
164,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
165,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
165,2,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
166,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
166,2,General symptom,General signs and symptoms NEC,General system disorders NEC,Genrl,N
166,3,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
167,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
168,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
168,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
168,3,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
168,4,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
168,5,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
168,6,Cardiac failure,Heart failures NEC,Heart failures,Card,N
168,7,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
168,8,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
168,9,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
168,10,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
168,11,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
168,12,Folliculitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
168,13,Heart rate abnormal,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
168,14,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
168,15,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
168,16,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
168,17,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
168,18,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
168,19,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
168,20,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
168,21,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
168,22,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
168,23,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
169,1,B-cell small lymphocytic lymphoma,B-cell small lymphocytic lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
169,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
169,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
169,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
169,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
169,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
169,7,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
169,8,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
169,9,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
170,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
170,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
170,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
171,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
172,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
173,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
174,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
174,2,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
175,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
176,1,Blood disorder,Haematological disorders,Haematological disorders NEC,Blood,N
177,1,Blood creatinine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
177,2,Blood potassium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
177,3,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
177,4,Lymphocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
177,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
177,6,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
178,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
178,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
179,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
179,2,Spinal fracture,Spinal fractures and dislocations,Bone and joint injuries,Inj&P,N
179,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
180,1,Mantle cell lymphoma,Mantle cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
180,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
181,1,Blood creatinine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
181,2,Blood phosphorus abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
181,3,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
181,4,Blood potassium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
181,5,Blood uric acid abnormal,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
181,6,Chronic lymphocytic leukaemia recurrent,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
181,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
181,8,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
181,9,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
181,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
181,11,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
181,12,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
181,13,Respiratory rate increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
181,14,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
181,15,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
182,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
183,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
184,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
184,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
185,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
185,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
185,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
185,4,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
185,5,Respiratory syncytial virus infection,Respiratory syncytial viral infections,Viral infectious disorders,Infec,N
186,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
186,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
187,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
187,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
187,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
187,4,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
188,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
189,1,Abdominal mass,Abdominal findings abnormal,Gastrointestinal signs and symptoms,Gastr,N
189,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
189,3,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,Y
190,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
190,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
190,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
191,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
191,2,Posterior reversible encephalopathy syndrome,Encephalopathies NEC,Encephalopathies,Nerv,N
192,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
192,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
192,3,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
193,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
193,2,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
193,3,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
193,4,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
193,5,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
193,6,Creatinine renal clearance decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
193,7,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
193,8,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
193,9,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
193,10,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
193,11,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
193,12,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
193,13,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
193,14,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
193,15,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
193,16,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
194,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
194,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
195,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
195,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
196,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
196,2,Creatinine renal clearance increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
196,3,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
197,1,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
198,1,B-cell small lymphocytic lymphoma,B-cell small lymphocytic lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
198,2,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
198,3,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
198,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
198,5,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
199,1,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
199,2,Chondrocalcinosis,Crystal arthropathic disorders,Joint disorders,Musc,N
199,3,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
199,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
200,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
200,2,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
200,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
200,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
201,1,B-cell small lymphocytic lymphoma recurrent,B-cell small lymphocytic lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
201,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
201,3,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
202,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
202,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
203,1,Acute graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
203,2,Allogenic stem cell transplantation,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
204,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
204,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
204,3,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
205,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
205,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
206,1,Mantle cell lymphoma refractory,Mantle cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
207,1,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
207,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
208,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
209,1,Disease risk factor,Social issues NEC,Lifestyle issues,SocCi,N
209,2,Learning disorder,Learning disorders,Cognitive and attention disorders and disturbances,Psych,N
210,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
210,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
210,3,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
210,4,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
210,5,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
210,6,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
210,7,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
211,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
211,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
211,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
211,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
211,5,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
212,1,Pneumonia influenzal,Influenza viral infections,Viral infectious disorders,Infec,N
212,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
213,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
214,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
214,2,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
214,3,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
214,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
214,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
215,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
216,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
216,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
217,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
218,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
219,1,Nephropathy toxic,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
220,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
221,1,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
221,2,Hodgkin's disease,Hodgkin's disease NEC,Lymphomas Hodgkin's disease,Neopl,N
221,3,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
222,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
222,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
223,1,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
224,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
224,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
225,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
225,2,Renal function test abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
226,1,IIIrd nerve paralysis,Eye movement disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
227,1,Chronic lymphocytic leukaemia recurrent,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
228,1,IIIrd nerve paralysis,Eye movement disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
229,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
229,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
229,3,Troponin I increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
230,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
230,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
230,3,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
231,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,Y
232,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
232,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
233,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
233,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
233,3,Renal injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
233,4,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
233,5,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
234,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
234,2,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
234,3,Fluid intake reduced,Fluid intake decreased,Electrolyte and fluid balance conditions,Metab,N
234,4,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
234,5,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
235,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
235,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
235,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
236,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
237,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
237,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
238,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
239,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
240,1,Chloroma,Leukaemias myeloid NEC,Leukaemias,Neopl,N
240,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
240,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
240,4,Subcutaneous abscess,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
241,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
241,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
241,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
242,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
243,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
243,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
244,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,Y
244,2,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
245,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
246,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
247,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
247,2,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
247,3,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
247,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
248,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
248,2,Cholecystitis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
248,3,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
248,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
248,5,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
248,6,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
249,1,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,Y
249,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
249,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
249,4,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
249,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
249,6,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
250,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
250,2,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
251,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
252,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
253,1,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
254,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
254,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
255,1,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
256,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
257,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
257,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
258,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
259,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
259,2,Lymphocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
260,1,Diffuse large B-cell lymphoma recurrent,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
260,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
261,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
261,2,T-cell prolymphocytic leukaemia,Leukaemias chronic T-cell,Leukaemias,Neopl,Y
262,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
263,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
263,2,Oesophageal stenosis,Oesophageal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
264,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
264,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
265,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
266,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
267,1,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
267,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
267,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
268,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
268,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
268,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
268,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
269,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
269,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
270,1,Squamous cell carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,Y
271,1,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
271,2,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
272,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
272,2,Post procedural discomfort,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
272,3,Procedural pain,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
273,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
273,2,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
273,3,Lung adenocarcinoma,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
273,4,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
274,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
275,1,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
276,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
277,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
278,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
279,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
279,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
279,3,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
279,4,Platelet disorder,Platelet disorders NEC,Platelet disorders,Blood,N
279,5,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
279,6,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
280,1,Angiodysplasia,Vascular malformations and acquired anomalies,Vascular disorders NEC,Vasc,N
280,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
280,3,Pre-existing condition improved,General signs and symptoms NEC,General system disorders NEC,Genrl,N
280,4,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
281,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
281,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
281,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
282,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
283,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
284,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
285,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
286,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
287,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
288,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
288,2,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
289,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
290,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
291,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
291,2,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
292,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
292,2,Exposure to SARS-CoV-2,Exposures to agents or circumstances NEC,"Exposures, chemical injuries and poisoning",Inj&P,N
293,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
293,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
294,1,Autoimmune haemolytic anaemia,Anaemias haemolytic immune,Haemolyses and related conditions,Blood,N
294,2,Autoimmune haemolytic anaemia,Anaemias haemolytic immune,Haemolyses and related conditions,Blood,N
295,1,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
296,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
297,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
298,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
299,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
299,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
300,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
301,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
302,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
302,2,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
302,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
303,1,Autoimmune haemolytic anaemia,Anaemias haemolytic immune,Haemolyses and related conditions,Blood,N
304,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
305,1,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
306,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
307,1,Autoimmune haemolytic anaemia,Anaemias haemolytic immune,Haemolyses and related conditions,Blood,N
308,1,Blood bicarbonate decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
308,2,Blood calcium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
308,3,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
308,4,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
308,5,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
308,6,Electrolyte imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
308,7,Eosinophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,8,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,9,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,10,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,11,Mean cell haemoglobin concentration decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,12,Mean cell volume increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,13,Monocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,14,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,15,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
308,16,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
308,17,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,18,Red cell distribution width increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
308,19,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
308,20,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
308,21,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
309,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
310,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
310,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
311,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
311,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
311,3,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
311,4,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
312,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
312,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
313,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
313,2,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
313,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
314,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
314,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
314,3,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
315,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
315,2,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
316,1,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
317,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
317,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
317,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
318,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
318,2,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
318,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
319,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
319,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
320,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
320,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
320,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
320,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
321,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
321,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
321,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
321,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
322,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
322,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
322,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
322,4,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
323,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
323,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
324,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
324,2,Minimal residual disease,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
324,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
325,1,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
326,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
326,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
327,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
327,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
327,3,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
327,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
327,5,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
328,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
328,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
328,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
329,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
329,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
330,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
331,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
332,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
332,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
332,3,Herpes simplex,Herpes viral infections,Viral infectious disorders,Infec,N
332,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
332,5,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
332,6,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
333,1,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
333,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
334,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
335,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
336,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
337,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
338,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
338,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
338,3,Transplant,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
339,1,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
339,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
340,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
340,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
340,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
341,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
341,2,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,Y
342,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
342,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
342,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
343,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
343,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
344,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
345,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
346,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
346,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
347,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
348,1,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
349,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
349,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
349,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
349,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
349,5,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
350,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
350,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
350,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
350,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
351,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
351,2,Lymphocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
351,3,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
352,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
352,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
353,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
353,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
353,3,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
353,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
353,5,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
354,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
355,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
355,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
355,3,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
355,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
355,5,Electrolyte imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
355,6,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
355,7,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
355,8,Inflammatory marker increased,Chemistry analyses NEC,Protein and chemistry analyses NEC,Inv,N
355,9,Pulseless electrical activity,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
355,10,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
355,11,Tachypnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
355,12,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
356,1,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
357,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
357,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
358,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
358,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
359,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
359,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
359,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
360,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
361,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
362,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
363,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
364,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
365,1,Blood calcium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
365,2,Chronic lymphocytic leukaemia recurrent,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
365,3,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
366,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
367,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
368,1,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
369,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
370,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
370,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
371,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
372,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
372,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
373,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
374,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
375,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
376,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
377,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
378,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
378,2,Blood uric acid abnormal,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
378,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
378,4,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
379,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
380,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
380,2,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
380,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
380,4,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
380,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
380,6,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
380,7,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
380,8,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
380,9,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
380,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
380,11,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
380,12,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
380,13,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
380,14,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
380,15,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
380,16,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
381,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
381,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
382,1,Chronic lymphocytic leukaemia recurrent,Leukaemias chronic lymphocytic,Leukaemias,Neopl,Y
383,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
384,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
385,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
386,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
387,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
387,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
387,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
388,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
388,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
389,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
389,2,Cardiomegaly,Myocardial disorders NEC,Myocardial disorders,Card,N
389,3,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
389,4,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
390,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
391,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
392,1,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
392,2,Pulmonary cavitation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
392,3,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
393,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
394,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
395,1,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
395,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
396,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
397,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
398,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
399,1,Bone marrow disorder,Haematological disorders,Haematological disorders NEC,Blood,N
400,1,Foot deformity,Extremity deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
401,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
401,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
402,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,Y
403,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
404,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
404,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
405,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
406,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
407,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
408,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
408,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
408,3,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
408,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
409,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
410,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
411,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,Y
411,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
412,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
412,2,Muscle fatigue,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
413,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
414,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
414,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
414,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
415,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
415,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
416,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
417,1,Foot deformity,Extremity deformities,Musculoskeletal and connective tissue deformities (incl intervertebral disc disorders),Musc,N
417,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
418,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
418,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
419,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
419,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
419,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
420,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
420,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
421,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
421,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
422,1,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
423,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
424,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
424,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
425,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
426,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
426,2,Peritoneal dialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
426,3,Post procedural sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
426,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
427,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
428,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
429,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
430,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
430,2,Cytomegalovirus colitis,Cytomegaloviral infections,Viral infectious disorders,Infec,N
430,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
430,4,Diarrhoea haemorrhagic,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
430,5,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
430,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
431,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
431,2,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
432,1,Cytomegalovirus colitis,Cytomegaloviral infections,Viral infectious disorders,Infec,N
432,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
433,1,Haematotoxicity,Haematological disorders,Haematological disorders NEC,Blood,N
434,1,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,N
434,2,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
434,3,Mean cell haemoglobin increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
434,4,Monocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
434,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
434,6,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
434,7,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
434,8,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
434,9,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
434,10,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
435,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
436,1,Splenic rupture,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
437,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
438,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
439,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
439,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
440,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
440,2,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
440,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
440,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
440,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
440,6,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
440,7,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
440,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
441,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
441,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
442,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
442,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
443,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
444,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
445,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
445,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
446,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
446,2,Cerebral thrombosis,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
446,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
446,4,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
446,5,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
447,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
448,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
448,2,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
448,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
449,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
450,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
451,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
452,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
453,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
453,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
454,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
455,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
456,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
457,1,Migraine,Migraine headaches,Headaches,Nerv,N
458,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
458,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
459,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
460,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
460,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
461,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
462,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
462,2,Major depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
462,3,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
463,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
464,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
464,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
465,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
466,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
467,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
468,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
468,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
469,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
470,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
470,2,Squamous cell carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
471,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
471,2,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
472,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
472,2,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
472,3,Hodgkin's disease,Hodgkin's disease NEC,Lymphomas Hodgkin's disease,Neopl,N
473,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
474,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
475,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
476,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
477,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
478,1,Body temperature decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
479,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
480,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
480,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
481,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
482,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
483,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
484,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
485,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
486,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
486,2,Cholecystectomy,Biliary tract and gallbladder therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
486,3,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
486,4,Mantle cell lymphoma,Mantle cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
487,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
487,2,Ocular toxicity,Ocular injuries NEC,Ocular injuries,Eye,N
487,3,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
487,4,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
487,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
488,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
489,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
490,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
490,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
491,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
491,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
492,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
493,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
494,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
494,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
494,3,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
494,4,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
494,5,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
494,6,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
494,7,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
494,8,Coronary artery bypass,Arterial therapeutic procedures (excl aortic),Vascular therapeutic procedures,Surg,N
494,9,Death,Death and sudden death,Fatal outcomes,Genrl,Y
494,10,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
494,11,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
494,12,Lymphocyte count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
494,13,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
494,14,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
494,15,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
494,16,Neutrophil count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
494,17,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
494,18,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
494,19,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
494,20,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
494,21,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
494,22,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
494,23,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
495,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
496,1,Malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
497,1,Blood phosphorus increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
497,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
497,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
498,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
499,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
500,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
501,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
501,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
502,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
502,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
503,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
504,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
504,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
505,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
506,1,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
507,1,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
508,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
509,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
510,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
511,1,Accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
511,2,Anal inflammation,Anal and rectal signs and symptoms,Anal and rectal conditions NEC,Gastr,N
511,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
511,4,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
511,5,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
511,6,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
511,7,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
511,8,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
511,9,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
511,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
511,11,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
511,12,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
511,13,Proctalgia,Anal and rectal pains,Anal and rectal conditions NEC,Gastr,N
511,14,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
511,15,SARS-CoV-2 test negative,Virus identification and serology,Microbiology and serology investigations,Inv,N
511,16,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
512,1,Bacterial infection,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
512,2,Cystitis haemorrhagic,Bladder infections and inflammations,Bladder and bladder neck disorders (excl calculi),Renal,N
513,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
513,2,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
513,3,TP53 gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
514,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
515,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
515,2,Minimal residual disease,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
515,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
516,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
516,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
517,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
517,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
517,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
518,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
518,2,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
518,3,Pemphigoid,Bullous conditions,Epidermal and dermal conditions,Skin,N
518,4,Pemphigus,Bullous conditions,Epidermal and dermal conditions,Skin,N
518,5,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
518,6,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,Y
519,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
520,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
521,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
521,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
522,1,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
522,2,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
522,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
523,1,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
523,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
523,3,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
524,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
524,2,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
525,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
526,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
526,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
527,1,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
528,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
529,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
529,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
530,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
530,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
531,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
532,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
532,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
532,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
533,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
534,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
535,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
536,1,Dysplasia,Trophic disorders,Tissue disorders NEC,Genrl,N
536,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
536,3,Rhinitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
537,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
537,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
537,3,Pericarditis,Noninfectious pericarditis,Pericardial disorders,Card,N
537,4,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
537,5,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
538,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
539,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
539,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
540,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,Y
541,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
542,1,Granuloma,Inflammations,General system disorders NEC,Genrl,N
542,2,Metastases to meninges,Metastases to specified sites,Metastases,Neopl,N
542,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
542,4,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
543,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
543,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
544,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
545,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
546,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
546,2,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
546,3,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
547,1,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
548,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
548,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
549,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
550,1,Bacterial infection,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
550,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
550,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
551,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
552,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
552,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
553,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
553,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
554,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
554,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
555,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
555,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
556,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
557,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
557,2,Bilirubin conjugated increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
557,3,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
558,1,Gouty tophus,Crystal arthropathic disorders,Joint disorders,Musc,N
558,2,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
559,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
560,1,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
560,2,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
561,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
561,2,Respiratory syncytial virus infection,Respiratory syncytial viral infections,Viral infectious disorders,Infec,N
562,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
562,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
562,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
563,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
563,2,Food poisoning,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
563,3,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
563,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
563,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
564,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
564,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
565,1,Culture urine positive,Microbiology and serology tests NEC,Microbiology and serology investigations,Inv,N
565,2,Granuloma,Inflammations,General system disorders NEC,Genrl,N
565,3,Metastases to meninges,Metastases to specified sites,Metastases,Neopl,N
565,4,Physical disability,Disability issues,Lifestyle issues,SocCi,N
565,5,Rehabilitation therapy,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
565,6,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
565,7,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
565,8,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
566,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
566,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
567,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
567,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
568,1,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
569,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
570,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
570,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
571,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
571,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
572,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
573,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
573,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
574,1,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
574,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
574,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
574,4,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
574,5,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
575,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
575,2,Blood phosphorus decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
575,3,Hyperphosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
576,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
576,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
577,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
577,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
577,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
577,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
578,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
578,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
578,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
578,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
578,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
578,6,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
578,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
578,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
579,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
580,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
580,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
580,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
580,4,Squamous cell carcinoma of head and neck,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
580,5,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
581,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
582,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
583,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
584,1,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
585,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
585,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
586,1,Monocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
586,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
586,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
587,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
587,2,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
588,1,Transitional cell carcinoma,Urinary tract neoplasms malignant NEC,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
589,1,Accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
589,2,Anal inflammation,Anal and rectal signs and symptoms,Anal and rectal conditions NEC,Gastr,N
589,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
589,4,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
589,5,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
589,6,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
589,7,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
589,8,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
589,9,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
589,10,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
589,11,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
589,12,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
589,13,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
589,14,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
589,15,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
589,16,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
589,17,Proctalgia,Anal and rectal pains,Anal and rectal conditions NEC,Gastr,N
589,18,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
589,19,SARS-CoV-2 test negative,Virus identification and serology,Microbiology and serology investigations,Inv,N
589,20,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
590,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
590,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
591,1,Cushingoid,Adrenal cortical hyperfunctions,Adrenal gland disorders,Endo,N
592,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
593,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
594,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
595,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
596,1,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
597,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
597,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
597,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
597,4,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
597,5,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
598,1,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
599,1,Cushingoid,Adrenal cortical hyperfunctions,Adrenal gland disorders,Endo,N
600,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
600,2,Gastrointestinal toxicity,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
601,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
602,1,Chronic lymphocytic leukaemia recurrent,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
603,1,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
603,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
603,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
604,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
604,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
604,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
605,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
605,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
606,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
607,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,Y
608,1,Aortic disorder,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
608,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
608,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
608,4,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
608,5,Venous aneurysm,Aneurysms and dissections non-site specific,Aneurysms and artery dissections,Vasc,N
609,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
610,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
611,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
611,2,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
611,3,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
611,4,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
611,5,Lymphocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
611,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
611,7,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
612,1,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
613,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
613,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
614,1,Pituitary apoplexy,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
615,1,Chondrocalcinosis,Crystal arthropathic disorders,Joint disorders,Musc,N
616,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
616,2,Karyotype analysis abnormal,Chromosome analyses,Cytogenetic investigations and genetic analyses,Inv,N
617,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
618,1,Crystal arthropathy,Crystal arthropathic disorders,Joint disorders,Musc,N
619,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
619,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
620,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
620,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,Y
621,1,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
622,1,Heart rate irregular,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
623,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
623,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
623,3,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
624,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
624,2,Torsade de pointes,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
625,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
626,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
627,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
628,1,Metastatic malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
629,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
629,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
630,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
631,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
631,2,Abdominal rigidity,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
631,3,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
631,4,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
631,5,Amylase increased,Digestive enzymes,Gastrointestinal investigations,Inv,N
631,6,Aortic aneurysm,Aortic aneurysms and dissections,Aneurysms and artery dissections,Vasc,N
631,7,Gastric dilatation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
631,8,Gastric volvulus,Gastric and pyloric stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
631,9,Hepatic cyst,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
631,10,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
631,11,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
631,12,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
631,13,Pancreatitis relapsing,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
631,14,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
632,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
632,2,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
633,1,Epstein-Barr virus test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
633,2,Hodgkin's disease,Hodgkin's disease NEC,Lymphomas Hodgkin's disease,Neopl,N
633,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
633,4,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
633,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
633,6,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
633,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
633,8,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
634,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,Y
634,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
635,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
635,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
635,3,Ventricular fibrillation,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
636,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
636,2,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,N
636,3,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
636,4,Platelet transfusion,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
636,5,Red blood cell transfusion,Blood and blood product treatment,Haematological and lymphoid tissue therapeutic procedures,Surg,N
637,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
637,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
638,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
638,2,Injection site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
639,1,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,N
639,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
639,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
639,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
640,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
640,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
640,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
640,4,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
641,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
641,2,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
641,3,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
642,1,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
642,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
643,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
644,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
644,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
645,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
645,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
646,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
646,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
646,3,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
647,1,Administration site rash,Administration site reactions NEC,Administration site reactions,Genrl,N
647,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
648,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
649,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
650,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
650,2,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
651,1,Progressive multifocal leukoencephalopathy,Polyomavirus infections,Viral infectious disorders,Infec,N
652,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
652,2,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
653,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
654,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
655,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
655,2,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
655,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
655,4,Prescription drug used without a prescription,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
656,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
656,2,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
656,3,Prescription drug used without a prescription,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
657,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
657,2,TP53 gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
658,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
658,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
658,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
658,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
658,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
658,6,Faeces soft,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
658,7,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
658,8,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
658,9,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
659,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
659,2,Tumour lysis syndrome,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
660,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
660,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
660,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
660,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
660,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
660,6,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
660,7,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
661,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
661,2,Diastolic dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
661,3,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
661,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
662,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
662,2,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
662,3,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
662,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
662,5,Proctalgia,Anal and rectal pains,Anal and rectal conditions NEC,Gastr,N
663,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
664,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
664,2,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
664,3,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
664,4,Porphyria,Inborn errors of porphyrin metabolism,Metabolic and nutritional disorders congenital,Cong,N
664,5,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
665,1,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
665,2,Richter's syndrome,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
666,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
666,2,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
666,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
